From 243 patients with traceable sCD163 levels at the time of NAFLD diagnosis, 13 patients had HCC onset and 15 patients died (10 patients had liver-related deaths, 3 patients had cancers of other organs, and two patients had cardiovascular events). This evidence concerns the gene CD163 and hepatocellular carcinoma.